Cargando…

Proteoglycan-targeting applied to hypoxia-activated prodrug therapy in chondrosarcoma: first proof-of-concept

Due to its abundant chondrogenic matrix and hypoxic tissue, chondrosarcoma is chemo- and radio-resistant. Our group has developed a proteoglycan targeting strategy by using a quaternary ammonium (QA) function as a carrier of DNA alkylating agents to chondrosarcoma environment. Here, we assessed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voissiere, Aurélien, Weber, Valérie, Gerard, Yvain, Rédini, Françoise, Raes, Florian, Chezal, Jean-Michel, Degoul, Françoise, Peyrode, Caroline, Miot-Noirault, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707064/ https://www.ncbi.nlm.nih.gov/pubmed/29221170 http://dx.doi.org/10.18632/oncotarget.21337

Ejemplares similares

Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing
por: Voissiere, Aurélien, et al.
Publicado: (2017)

A“Proteoglycan Targeting Strategy” for the Scintigraphic Imaging and Monitoring of the Swarm Rat Chondrosarcoma Orthotopic Model
por: Peyrode, Caroline, et al.
Publicado: (2011)

(99m)Tc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model
por: Miot-Noirault, Elisabeth, et al.
Publicado: (2013)

Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept
por: Rondon, Aurélie, et al.
Publicado: (2019)

Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms()
por: Akil, Hussein, et al.
Publicado: (2019)

A Convenient Route to New (Radio)Fluorinated and (Radio)Iodinated Cyclic Tyrosine Analogs
por: Chao, Maria Noelia, et al.
Publicado: (2022)

Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy()
por: Rbah-Vidal, Latifa, et al.
Publicado: (2016)

Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy
por: Viallard, Claire, et al.
Publicado: (2016)

Antibody PEGylation in bioorthogonal pretargeting with trans-cyclooctene/tetrazine cycloaddition: in vitro and in vivo evaluation in colorectal cancer models
por: Rondon, Aurélie, et al.
Publicado: (2017)

Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer
por: Maisonial-Besset, Aurelie, et al.
Publicado: (2017)

N-(4-iodophenyl)-N′-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice
por: Borel, M, et al.
Publicado: (2007)

Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression
por: Nicolle, Rémy, et al.
Publicado: (2019)

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy
por: Nota, Sjoerd P. F. T., et al.
Publicado: (2022)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for the (64)Cu-Labelling of Immunoconjugates
por: Maisonial-Besset, Aurélie, et al.
Publicado: (2022)

Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
por: Rondon, Aurélie, et al.
Publicado: (2021)

Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
por: Redini, Françoise, et al.
Publicado: (2015)

Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment
por: Verrecchia, Franck, et al.
Publicado: (2018)

[(18)F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer
por: Jouberton, Elodie, et al.
Publicado: (2020)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

Stimuli-responsive oligonucleotides in prodrug-based approaches for gene silencing
por: Debart, Françoise, et al.
Publicado: (2018)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

Proof of Concept of the Radiosensitizing Effect of Gadolinium Oxide Nanoparticles in Cell Spheroids and a Tumor-Implanted Murine Model of Chondrosarcoma
por: Aloy, Marie-Thérèse, et al.
Publicado: (2022)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Applied signal processing: a MATLAB based proof of concept
por: Dutoit, Thierry, et al.
Publicado: (2009)

Applied proof theory: proof interpretations and their use in mathematics
por: Kohlenbach, Ulrich
Publicado: (2008)

Assessment of (99m)Tc-NTP 15-5 uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT)
por: Thivat, Emilie, et al.
Publicado: (2022)

Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mIDH1 Mutant Tumours
por: Weber, Valérie, et al.
Publicado: (2022)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
por: Hunter, Francis W, et al.
Publicado: (2016)

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
por: Liu, Shujing, et al.
Publicado: (2017)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Hypoxia-Activated Albumin-Binding Exatecan Prodrug for Cancer Therapy
por: Cheng, Zhiyang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vihfbvg32nkdngoe85k1ic51kf